Biogen Signs an Exclusive Worldwide License Agreement with Sangamo to Develop Gene Therapies for Multiple Neurological Diseases

 Biogen Signs an Exclusive Worldwide License Agreement with Sangamo to Develop Gene Therapies for Multiple Neurological Diseases

Biogen Signs an Exclusive Worldwide License Agreement with Sangamo to Develop Gene Therapies for Multiple Neurological Diseases

Shots:

  • Sangamo to receive $350 million upfront, including $125M license fee & $225M equity investment in Sangamo’s stock or ~24M shares at $9.21/share and is eligible to receive $2.37B as milestones along with royalties on sales of the therapies
  • Biogen to get an exclusive WW right of ST-501 for tauopathies including AD, ST-502 for synucleinopathies including PD and third neuromuscular disease target with exclusive rights for 9 additional targets for 5yrs. The GMP manufacturing activities for the first 3 products will be processed by Sangamo later Biogen will be responsible beyond the first clinical study for each of the first 3 products
  • Sangamo will be responsible for early research activities for which cost will be shared b/w the companies while Biogen will take the responsibility and costs for the IND, clinical development, related regulatory interaction and global commercialization of therapies

Click here ­to­ read full press release/ article | Ref: Biogen | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post